{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06304636",
            "orgStudyIdInfo": {
                "id": "DC15-MM-01"
            },
            "organization": {
                "fullName": "Cartesian Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma",
            "officialTitle": "Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma",
            "acronym": "DC15-MM-01",
            "therapeuticArea": [
                "Other"
            ],
            "study": "descartes-for-patients-with-relapsed-refractory-multiple-myeloma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2024-06-19",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-10-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-28",
            "studyFirstSubmitQcDate": "2024-03-08",
            "studyFirstPostDateStruct": {
                "date": "2024-03-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-13",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Cartesian Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase I dose-escalation study to evaluate the safety, tolerability and preliminary efficacy of an autologous BCMA-targeting RNA-engineered CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma. The cell product is referred to as Descartes-15"
        },
        "conditionsModule": {
            "conditions": [
                "Refractory Multiple Myeloma",
                "Relapsed Multiple Myeloma"
            ],
            "keywords": [
                "Relapsed/Refractory",
                "Relapsed Myeloma",
                "Refractory Myeloma",
                "Multiple Myeloma",
                "Car-T",
                "CART",
                "Descartes-15",
                "Descartes",
                "Myeloma",
                "T cells",
                "cell gene"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Study consists of two parts. Part 1 is a single-arm dose escalation study. Part 2 is a dose-expansion study with 2 arms.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 41,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1 Descartes-15 with lymphodepletion",
                    "type": "EXPERIMENTAL",
                    "description": "Intra-patient dose escalation arm with three dose levels over the course of six infusions of cell product. Patients will receive lymphodepletion prior to initiating cell therapy.",
                    "interventionNames": [
                        "Drug: Descartes-15"
                    ]
                },
                {
                    "label": "Part 2 Arm 1 Descartes-15 with lymphodepletion",
                    "type": "EXPERIMENTAL",
                    "description": "Descartes-15 infusions at the maximum tolerated dose level from Part 1. Patients will receive lymphodepletion prior to initiating cell therapy.",
                    "interventionNames": [
                        "Drug: Descartes-15"
                    ]
                },
                {
                    "label": "Part 2 Arm 2 Descartes-15 without lymphodepletion",
                    "type": "EXPERIMENTAL",
                    "description": "Descartes-15 infusions at the maximum tolerated dose level from Part 1. Patients will not receive lymphodepletion prior to initiating cell therapy.",
                    "interventionNames": [
                        "Drug: Descartes-15"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Descartes-15",
                    "description": "Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA",
                    "armGroupLabels": [
                        "Part 1 Descartes-15 with lymphodepletion",
                        "Part 2 Arm 1 Descartes-15 with lymphodepletion",
                        "Part 2 Arm 2 Descartes-15 without lymphodepletion"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Determine the safety of Descartes-15 in patients with relapsed/refractory multiple myeloma (R/R MM)",
                    "description": "Results will be descriptive. Safety and tolerability endpoints are adverse events and serious adverse events as proportion of all participants at a given dose level and in the overall study population.",
                    "timeFrame": "Day -60 to Month 12"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "To assess the anti-myeloma activity of Descartes-15, as measured by IMWG response criteria and progression-free survival",
                    "description": "Efficacy will be assessed by descriptive statistics of treatment response per IMWG criteria. Efficacy endpoints will be reported as proportion of participants achieving Stable Disease (SD), Partial Response (PR), Very Good Partial Response (VGPR), Complete Response (CR) and stringent Complete Response (sCR) as the best response at a given dose level and in the overall study population.",
                    "timeFrame": "Day 1 to Month 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria\n\n* Patients must be 18 years of age or older at the time of enrollment.\n* Patients must be diagnosed with active and measurable relapsed/refractory multiple myeloma.\n* Patients must have failed at least 3 prior lines of therapy which must have included an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 drug or biologic. Failure of treatment and measurable myeloma disease are defined as per 2016 IMWG criteria.\n* Patients must have clinical performance status of ECOG 0-2.\n* Patients must have adequate vital organ function as defined by:\n* Hemoglobin \u22658 g/dL\n* Absolute neutrophil count \\> 1000/ mm3\n* Platelets \\> 50,000/mm3\n* ALT/AST levels lower than 3-fold of normal\n* Creatinine clearance \u226545 mL/min/1.73 m2\n* Normal cardiac and pulmonary function\n* No thromboembolic events in the past 3 months\n* No heparin allergy or active infection\n\nExclusion Criteria\n\n* Patients who have any active and uncontrolled infection.\n* Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine or systemic steroids above 40 mg/day prednisone equivalent).\n* Patients who have active central nervous system disease.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Trial Central Mailbox",
                    "role": "CONTACT",
                    "phone": "302-648-6497",
                    "email": "trials@cartesiantx.com"
                }
            ],
            "locations": [
                {
                    "facility": "Center for Cancer and Blood Disorders (AON)",
                    "status": "RECRUITING",
                    "city": "Bethesda",
                    "state": "Maryland",
                    "zip": "20817",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.98067,
                        "lon": -77.10026
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009101",
                    "term": "Multiple Myeloma"
                },
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}